Market Research Future (MRFR) has announced a new release on the global ventilator-associated pneumonia market. The report takes into account the global ventilator-associated pneumonia market’s historical growth trajectory and major growth drivers and restraints in order to come up with a reliable projection for the market’s likely growth trajectory over the forecast period from 2018 to 2023.
Ventilator-associated pneumonia is caused when a patient with an underlying condition associated with the disease is kept on ventilators for a long period of time. The conditions associated with the disease include cardiovascular disease, neurological diseases, or trauma. Blunt or penetrating trauma may play a key role in the development of the disease, with blunt trauma exhibiting a higher statistical correlation with the disease than penetrating trauma. Other physical factors such as the elevation of the head of the bed can also play a part in the development of ventilator-associated pneumonia, although the role played by such factors can be subtle and not quantifiable. The presence of a flat bed can exacerbate the buildup of fluids within the lungs, causing ventilator-associated pneumonia. Higher duration of being placed on a ventilator is also a causative factor for the onset of ventilator-associated pneumonia.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/1377
The growing demand to eliminate hospital-acquired infections (HAI) is likely to be a major driver for the global ventilator-associated pneumonia market over the forecast period. The rising prevalence of cardiovascular and particularly lung diseases is also likely to be a key driver for the ventilator-associated pneumonia market over the forecast period. The increasing geriatric population around the world is also likely to be a major driver for the global ventilator-associated pneumonia market, as older people are not only more prone to contracting pneumonia, but are also more likely to be placed on ventilators.
The global ventilator-associated pneumonia market is segmented on the basis of diagnosis, mode of treatment, end use, and region.
On the basis of diagnosis, the global ventilator-associated pneumonia market is segmented into clinical examination, radiological examination, microbiological analysis, and others. The microbiological analysis segment is further sub-segmented into blood and pleural fluid cultures, nonquantitative or semi-quantitative airway sampling, and quantitative cultures of airway specimens.
By mode of treatment, the global ventilator-associated pneumonia market is segmented into home care, hospital care, and others.
On the basis of end use, the global ventilator-associated pneumonia market is segmented into hospitals and clinics, ambulatory care centers, emergency medical services, and research centers.
The global ventilatory-associated pneumonia market is segmented on the basis of region into the Americas (North and South America), Europe (Western and Eastern Europe), Asia Pacific, and the Middle East and Africa.
North America and Europe are likely to be the major regional segments of the global ventilator-associated pneumonia market over the forecast period due to the growing geriatric population and growing prevalence of lung diseases in these regions. The growing awareness about hospital-acquired infections in the region has led to growing efforts to wipe them out. This is also likely to be a key driver for the ventilator-associated pneumonia market in these regions. North America and Europe have been at the forefront of the movement to identify the threat of hospital-acquired infections and nullify it. North America is likely to lead the global ventilator-associated pneumonia market over the forecast period, with Europe coming in a close second.
The Asia Pacific ventilator-associated pneumonia market is likely to exhibit the highest growth rate over the forecast period due to the growing prevalence of respiratory disorders as well as the increasing healthcare expenditure in the region. The adoption of ventilators is likely to grow in Asia Pacific over the forecast period, as governments in the region have made significant commitments towards growth of the healthcare sector. This could emerge as a key driver for the ventilator-associated pneumonia market over the forecast period.
Leading players in the global ventilator-associated pneumonia market include Merck & Co. Inc., AstraZeneca, Nabriva Therapeutics AG, MedImmune, and Adenium Biotech ApS.
In January 2019, Liberate Medical received a Breakthrough Device designation from the U.S. FDA for its VentFree muscle stimulator. The muscle stimulator shortens the need for ventilator support and thus could help reduce the prevalence of ventilator-associated pneumonia by striking at the root cause of the problem.
Read Comprehensive Overview of Report @ https://www.marketresearchfuture.com/reports/ventilator-associated-pneumonia-vap-market-1377
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Phone: +1 646 845 9312